Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAN-101 in adults with celiac disease undergoing gluten challenge
NL-OMON60458Phase 2Completed
- Sponsor
- Anokion
- Start
- Jun 2024
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of KAN-101 in celiac disease, sponsored by Anokion. Primary endpoint: Change from baseline in villus-height:crypt depth ratio. Started Jun 2024; status: completed.
02
Drugs
KAN-101
03
Conditions
celiac disease
Beyond the preview
Go deeper on NL-OMON60458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60458.